Optogenetics Global Market Report 2024

The optogenetics market size has grown rapidly in recent years. It will grow from $31.9 billion in 2023 to $36.81 billion in 2024 at a compound annual growth rate (CAGR) of 15.4%. The growth observed in the historical period can be attributed to factors such as the rise in neurological disorders, increased funding in life sciences, advancements in drug discovery and development, the mapping of neural circuits, the application of optogenetics in drug screening, and progress in neurophotonics.

The optogenetics market size is expected to see rapid growth in the next few years. It will grow to $63.33 billion in 2028 at a compound annual growth rate (CAGR) of 14.5%. The anticipated growth in the forecast period can be attributed to factors such as the expansion of therapeutic applications, increased focus on clinical trials and translation, extending applications into non-neuronal cells, the utilization of optogenetics in brain-machine interfaces, and the development of novel light-sensitive proteins. Major trends expected in this period include advancements in optogenetic tools and technologies, collaborations with pharmaceutical companies, the integration of optogenetics in drug discovery and development, the expansion of applications into non-neural cell types, and the integration of optogenetics with other imaging technologies.

The optogenetics market is anticipated to experience growth due to the rising prevalence of Parkinson's disease (PD) and epilepsy worldwide. Parkinson's disease is characterized by degeneration in the brain, leading to motor symptoms such as slow movement, tremors, rigidity, and imbalance, along with cognitive decline, mental health issues, sleep disturbances, pain, and sensory problems. Optogenetic therapy employs proteins responsive to specific light wavelengths, produced through gene therapy techniques, to treat Parkinson's disease by either activating or deactivating these proteins with specific types of light, ultimately normalizing brain function. In December 2022, The Parkinson’s Foundation reported a significant increase in annual PD diagnoses to nearly 90,000, up from the previous estimate of 60,000. The number of individuals living with PD in the U.S. is expected to rise to 1.2 million by 2030 from 930,000 in 2020, driving the growth of the optogenetics market.

The optogenetics market is also fueled by increased funding for neuroscience research, which involves the scientific study of the nervous system, including the brain and peripheral nerves. Optogenetics, a cutting-edge technique in neuroscience, utilizes light to precisely control and manipulate specific neurons in living tissues, providing researchers with a powerful tool to understand neural circuits. In March 2023, the National Institutes of Health (NIH) reported approximately $11.3 billion in funding for neuroscience in fiscal year 2022, with projections indicating an expected increase to $12.1 billion by 2023. This increased funding is expected to drive the growth of the optogenetics market.

A prevailing trend in the optogenetics market is the emphasis on developing innovative systems, a strategy gaining traction among major companies in the industry. These companies are actively engaged in creating advanced tools and systems for optogenetics, incorporating state-of-the-art technologies to maintain their market standing. For instance, in June 2022, Bruker Corporation, a prominent US-based manufacturer of optogenetic tools, introduced NeuraLight 3D Ultra. This innovative product is an enhanced 3D holographic stimulation module designed to support cutting-edge neuroscience and optogenetics research applications, particularly tailored for use with Bruker’s Ultima 2Pplus Multiphoton Microscope. NeuraLight 3D Ultra facilitates in-depth functional research on neural networks and brain computation through its advanced 3D holographic photostimulation capabilities.

Major players in the optogenetics market are also directing their efforts towards the development of advanced products, with a focus on three-photon (3P) imaging solutions, aiming to gain a competitive edge and boost revenue. The three-photon imaging solution represents an integrated and versatile ultrafast laser system meticulously crafted for advanced three-photon imaging in neuroscience research. Additionally, it offers functionalities for two-photon photostimulation and imaging in optogenetics applications. For instance, in June 2022, Coherent, Inc., a leading US-based company specializing in laser equipment, launched the Monaco 1300 - an all-in-one ultrafast 1300 nm light source. This cutting-edge device is specifically designed for three-photon (3P) imaging, featuring a switchable secondary output at 1035 nm to cater to two-photon (2P) photostimulation and imaging applications. The Monaco 1300, a single-box ultrafast laser, is engineered for 3-photon microscopy at 1300 nm and 2-photon optogenetics at 1035 nm, providing options for average power (1.5 W or 2.5 W), a pulse width of less than 50 fs, and various repetition rate choices (1, 2, or 4 MHz). This technological advancement equips researchers and businesses with advanced capabilities for precise imaging and optogenetic applications in the microscopy field. The comprehensive package of the Monaco 1300 includes the option for the widely favored Total Power Control (TPC) feature, allowing dynamic power attenuation and rapid optical gating on-the-fly.

In September 2021, Novartis AG, a Switzerland-based pharmaceutical giant, undertook the acquisition of Arctos Medical AG for an undisclosed amount. This strategic move is geared towards enhancing Novartis' presence in ophthalmology, strengthening its position in AAV-based gene therapy, and providing innovative treatments for patients experiencing severe vision loss. Arctos Medical, based in Switzerland, specializes in gene therapy and is particularly focused on optogenetic therapies.

Major companies operating in the optogenetics market report are Elliot Scientific Ltd., Shanghai Laser & Optics Century Co. Ltd., GenSight Biologics, Danaher Corporation, Coherent Inc., Thorlabs Inc., Prizmatix Ltd., Bruker Corporation, Judges Scientific Plc., Merck KGaA, The Jackson Laboratory, Noldus Information Technology BV, Applied Genetic Technologies Corporation, Circuit Therapeutics Inc., Bionic Sight LLC, Teledyne Photometrics, Campden Instruments, Nanoscope Therapeutics Inc., Laserglow Technologies, Hubner Group, Novartis, AbbVie, Physical Sciences Inc., Ray Therapeutics, OptoGenTech, opto biolabs, Neurolux, Ugenex Therapeutics, Scientifica, Cobolt Inc., Inscopix, Mightex Systems.

North America was the largest region in the optogenetics market in 2023. The regions covered in the optogenetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the optogenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main products associated with optogenetics include lasers, actuators, and sensors. A laser is a device that emits light through a process of optical amplification at specific wavelengths, producing a very narrow beam of light. These products find various applications in neuroscience, behavioral tracking, retinal disease treatment, and other related fields. End-users of optogenetics products include hospitals and clinics, diagnostics centers, research centers, and other institutions involved in scientific and medical research.

The optogenetic market research report is one of a series of new reports that provides optogenetics market statistics, including optogenetics industry global market size, regional shares, competitors with a optogenetics market share, detailed optogenetics market segments, market trends and opportunities, and any further data you may need to thrive in the optogenetics industry. This optogenetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.